Last reviewed · How we verify
NCT03846128: BIOSUNTOX
Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer
trial testing blood sample in Metastatic Kidney Cancer in 6 participants. Terminated before completion.
8 October 2021
Quick facts
| Lead sponsor | University Hospital, Rouen |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 6 |
| Start date | 3 June 2019 |
| Primary completion | 8 October 2021 |
| Estimated completion | 8 October 2021 |
| Sites | 1 location across France |
Drugs / interventions tested
- blood sample — full drug profile →
Conditions studied
- Metastatic Kidney Cancer — all drugs for Metastatic Kidney Cancer →
Sponsor
University Hospital, Rouen
Who can join
18 and older, any sex, with Metastatic Kidney Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients treated on the first line of Sunitinib-targeted therapy for metastatic kidney cancer. Collection of additional blood tubes during routine blood tests for patient follow-up, to evaluate the plasma concentration of Sunitinib and its active metabolite desethyl-Sunitinib (DES)
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
Bæk Møller N, Budolfsen C, Grimm D, Krüger M, et al · · 2019 · cited 43× · PMID 31547602 · DOI 10.3390/ijms20194712
Verify or expand the search:
- PubMed search for NCT03846128
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blood sample
Trials testing the same drug.
- NCT07370792 — Contribution of Optical Genome Mapping (OGM) in the Diagnosis of Multiple Congenital Malformations With or Without Intel · NA · recruiting
- NCT07273331 — Nursing Needs of Patients With Cirrhosis · enrolling by invitation
- NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
- NCT06968598 — Analysis of Early Neurodevelopmental Alterations in Bipolar Disorder Based on Cortical Organoid Models · NA · not yet recruiting
- NCT07332702 — Long Read Analysis in Spinal Muscular Atrophy - LOREASI · NA · recruiting
Other recruiting trials for Metastatic Kidney Cancer
Currently open trials in the same condition.
- NCT06364631 — CARE1 Pragmatic Clinical Trial · Phase 3 · recruiting
- NCT05796973 — Measuring Oncological Value of Exercise and Statin · Phase 3 · recruiting
- NCT04623502 — An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy · NA · recruiting
Other University Hospital, Rouen trials
Trials by the same sponsor.
- NCT07441564 — Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Jux · NA · not yet recruiting
- NCT07535944 — Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors · not yet recruiting
- NCT07464184 — Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension · NA · not yet recruiting
- NCT07359885 — Prediction of Postoperative Pulmonary Complications in Thoracic Surgery · not yet recruiting
- NCT07247500 — Impact of Reventilation After One-Lung Ventilation in Thoracic Surgery (OLVREEXP) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03846128 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Rouen
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03846128.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing